Metagenomi Therapeutics (MGX) Total Non-Current Liabilities (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Total Non-Current Liabilities data on file, last reported at $57.2 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $57.2 million, down 31.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.2 million (down 31.15% YoY), and the FY2025 annual result was $60.6 million, down 30.98% from the prior year.
• Total Non-Current Liabilities fell to $57.2 million in Q1 2026 per MGX's latest filing, from $60.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $144.6 million in Q4 2023 and troughed at $57.2 million in Q1 2026.
• A 4-year average of $92.2 million and a median of $85.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities tumbled 39.32% in 2024, then tumbled 30.98% in 2025.
• A 4-year view of Total Non-Current Liabilities shows it stood at $144.6 million in 2023, then tumbled by 39.32% to $87.7 million in 2024, then plunged by 30.98% to $60.6 million in 2025, then declined by 5.51% to $57.2 million in 2026.
• Business Quant data shows MGX's Total Non-Current Liabilities at $57.2 million in Q1 2026, $60.6 million in Q4 2025, and $67.6 million in Q3 2025.